Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma

被引:35
|
作者
Brims, Fraser [1 ,2 ,3 ]
机构
[1] Curtin Univ, Curtin Med Sch, Perth, WA 6845, Australia
[2] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA 6009, Australia
[3] Inst Resp Hlth, Natl Ctr Asbestos Related Dis, Perth, WA 6009, Australia
关键词
mesothelioma; asbestos; epidemiology; pleural disease; TO-LYMPHOCYTE RATIO; PROGNOSTIC-FACTORS; OPEN-LABEL; TALC PLEURODESIS; LUNG-CANCER; SOLUBLE MESOTHELIN; SERUM MESOTHELIN; PHASE-III; DIAGNOSIS; ASBESTOS;
D O I
10.3390/cancers13164194
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Mesothelioma is a cancer of the lining of the lungs caused by breathing in asbestos fibres. Asbestos was widely used in industry in the last century in most developed countries and is still present in many older buildings to this day. There is no known safe level of asbestos exposure. Symptoms of mesothelioma can include worsening breathlessness, chest pain and loss of weight. There is no cure, and the treatment of mesothelioma is limited, although there have been some recent improvements in therapy. Survival is very variable although most people live for around one year after diagnosis. Efforts to improve and maintain the quality of life for patients with mesothelioma remain a priority. Mesothelioma is a cancer predominantly of the pleural cavity. There is a clear association of exposure to asbestos with a dose dependent risk of mesothelioma. The incidence of mesothelioma in different countries reflect the historical patterns of commercial asbestos utilisation in the last century and predominant occupational exposures mean that mesothelioma is mostly seen in males. Modern imaging techniques and advances in immunohistochemical staining have contributed to an improved diagnosis of mesothelioma. There have also been recent advances in immune checkpoint inhibition, however, mesothelioma remains very challenging to manage, especially considering its limited response to conventional systemic anticancer therapy and that no cure exists. Palliative interventions and support remain paramount with a median survival of 9-12 months after diagnosis. The epidemiology and diagnosis of mesothelioma has been debated over previous decades, due to a number of factors, such as the long latent period following asbestos exposure and disease occurrence, the different potencies of the various forms of asbestos used commercially, the occurrence of mesothelioma in the peritoneal cavity and its heterogeneous pathological and cytological appearances. This review will describe the contemporary knowledge on the epidemiology of mesothelioma and provide an overview of the best clinical practice including diagnostic approaches and management.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Malignant Pleural Mesothelioma: Socioeconomic and Clinical Aspects
    Pandey, Swaroop Kumar
    Yadav, Neha
    Mishra, Anuja
    Sohal, Jagdip Singh
    Thakur, Komal
    Dwivedi-Agnihotri, Hemlata
    CURRENT CANCER THERAPY REVIEWS, 2024,
  • [2] International trends in the clinical epidemiology of malignant pleural mesothelioma
    Damhuis, Ronald A. M.
    van Meerbeeck, Jan P.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1147 - 1148
  • [3] MALIGNANT PLEURAL MESOTHELIOMA - CLINICAL ASPECTS AND TREATMENT RESULTS
    LEBLANC, P
    DESMEULES, M
    UNION MEDICALE DU CANADA, 1984, 113 (11): : 968 - 972
  • [4] EPIDEMIOLOGY AND PREVENTION OF MALIGNANT PLEURAL MESOTHELIOMA
    WOITOWITZ, HJ
    MEDIZINISCHE KLINIK, 1987, 82 (17) : 578 - &
  • [5] Clinical diagnosis of malignant pleural mesothelioma
    Bianco, Andrea
    Valente, Tullio
    De Rimini, Maria Luisa
    Sica, Giacomo
    Fiorelli, Alfonso
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S253 - S261
  • [6] Clinical presentation of malignant pleural mesothelioma
    Manzini, VD
    ANNALS OF ONCOLOGY, 2000, 11 : 6 - 6
  • [7] The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma
    Lettieri, Sara
    Bortolotto, Chandra
    Agustoni, Francesco
    Lococo, Filippo
    Lancia, Andrea
    Comoli, Patrizia
    Corsico, Angelo G.
    Stella, Giulia M.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (05) : 1 - 21
  • [8] Malignant pleural mesothelioma: New aspects of diagnosis and treatment
    Krzakowski, M
    PROCEEDINGS OF THE 9TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2004, : 33 - 38
  • [9] Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma
    Yamada, Shusai
    Tabata, Chiharu
    Tabata, Rie
    Fukuoka, Kazuya
    Nakano, Takashi
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (10) : 1721 - 1726
  • [10] Clinical findings and diagnosis of malignant pleural mesothelioma
    Sackmann, S.
    PNEUMOLOGE, 2010, 7 (01): : 19 - 27